TY  - JOUR
A1  - Benkert, Thomas F.
A1  - Dietz, Lena
A1  - Hartmann, Elena M.
A1  - Leich, Ellen
A1  - Rosenwald, Andreas
A1  - Serfling, Edgar
A1  - Buttmann, Mathias
A1  - Berberich-Siebelt, Friederike
T1  - Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis
N2  - Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic efficacy, treatment by natalizumab has been linked to progressive multifocal leukoencephalopathy (PML) as a serious adverse effect. Furthermore, drug cessation sometimes induces rebound disease activity of unknown etiology. Here we investigated whether binding of this adhesion-blocking antibody to T lymphocytes could modulate their phenotype by direct induction of intracellular signaling events. Primary CD4+ T lymphocytes either from healthy donors and treated with natalizumab in vitro or from MS patients receiving their very first dose of natalizumab were analyzed. Natalizumab induced a mild upregulation of IL-2, IFN-c and IL-17 expression in activated primary human CD4+ T cells propagated ex vivo from healthy donors, consistent with a pro-inflammatory costimulatory effect on lymphokine expression. Along with this, natalizumab binding triggered rapid MAPK/ERK phosphorylation. Furthermore, it decreased CD49d surface expression on effector cells within a few hours. Sustained CD49d downregulation could be attributed to integrin internalization and degradation. Importantly, also CD4+ T cells from some MS patients receiving their very first dose of natalizumab produced more IL-2, IFN-c and IL-17 already 24 h after infusion. Together these data indicate that in addition to its adhesion-blocking mode of action natalizumab possesses mild direct signaling capacities, which can support a pro-inflammatory phenotype of peripheral blood T lymphocytes. This might explain why a rebound of disease activity or IRIS is observed in some MS patients after natalizumab cessation.
KW  - Medizin
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-77905
ER  - 
TY  - JOUR
A1  - Effenberger, Madlen
A1  - Bommert, Kathryn S.
A1  - Kunz, Viktoria
A1  - Kruk, Jessica
A1  - Leich, Ellen
A1  - Rudelius, Martina
A1  - Bargou, Ralf
A1  - Bommert, Kurt
T1  - Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation
JF  - Oncotarget
N2  - Multiple Myeloma (MM) is an incurable hematological malignancy affecting millions of people worldwide. As in all tumor cells both glucose and more recently glutamine have been identified as important for MM cellular metabolism, however there is some dispute as to the role of glutamine in MM cell survival. Here we show that the small molecule inhibitor compound 968 effectively inhibits glutaminase and that this inhibition induces apoptosis in both human multiple myeloma cell lines (HMCLs) and primary patient material. The HMCL U266 which does not express MYC was insensitive to both glutamine removal and compound 968, but ectopic expression of MYC imparted sensitivity. Finally, we show that glutamine depletion is reflected by rapid loss of MYC protein which is independent of MYC transcription and post translational modifications. However, MYC loss is dependent on proteasomal activity, and this loss was paralleled by an equally rapid induction of apoptosis. These findings are in contrast to those of glucose depletion which largely affected rates of proliferation in HMCLs, but had no effects on either MYC expression or viability. Therefore, inhibition of glutaminolysis is effective at inducing apoptosis and thus serves as a possible therapeutic target in MM.
KW  - Multiple Myeloma
KW  - glutaminase inhibition
KW  - apoptosis
KW  - MYC
Y1  - 2017
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170168
VL  - 8
IS  - 49
ER  - 
TY  - JOUR
A1  - El-Mesery, Mohamed
A1  - Rosenthal, Tina
A1  - Rauert-Wunderlich, Hilka
A1  - Schreder, Martin
A1  - Stühmer, Thorsten
A1  - Leich, Ellen
A1  - Schlosser, Andreas
A1  - Ehrenschwender, Martin
A1  - Wajant, Harald
A1  - Siegmund, Daniela
T1  - The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death
JF  - Cell Death & Disease
N2  - The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase βTrCP. MLN4924 therefore inhibits also the βTrCP-dependent activation of the classical and the alternative NFĸB pathway. In this work, we found that a subgroup of multiple myeloma cell lines (e.g., RPMI-8226, MM.1S, KMS-12BM) and about half of the primary myeloma samples tested are sensitized to TNF-induced cell death by MLN4924. This correlated with MLN4924-mediated inhibition of TNF-induced activation of the classical NFκB pathway and reduced the efficacy of TNF-induced TNFR1 signaling complex formation. Interestingly, binding studies revealed a straightforward correlation between cell surface TNFR1 expression in multiple myeloma cell lines and their sensitivity for MLN4924/TNF-induced cell death. The cell surface expression levels of TNFR1 in the investigated MM cell lines largely correlated with TNFR1 mRNA expression. This suggests that the variable levels of cell surface expression of TNFR1 in myeloma cell lines are decisive for TNF/MLN4924 sensitivity. Indeed, introduction of TNFR1 into TNFR1-negative TNF/MLN4924-resistant KMS-11BM cells, was sufficient to sensitize this cell line for TNF/MLN4924-induced cell death. Thus, MLN4924 might be especially effective in myeloma patients with TNFR1+ myeloma cells and a TNFhigh tumor microenvironment.
KW  - cancer therapy
KW  - tumour-necrosis factors
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226666
VL  - 10
ER  - 
TY  - JOUR
A1  - Keppler, Sarah
A1  - Weißbach, Susann
A1  - Langer, Christian
A1  - Knop, Stefan
A1  - Pischimarov, Jordan
A1  - Kull, Miriam
A1  - Stühmer, Thorsten
A1  - Steinbrunn, Torsten
A1  - Bargou, Ralf
A1  - Einsele, Hermann
A1  - Rosenwald, Andreas
A1  - Leich, Ellen
T1  - Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
JF  - Oncotarget
N2  - Multiple myeloma (MM) is a plasma cell disorder that is characterized by a great genetic heterogeneity. Recent next generation sequencing studies revealed an accumulation of tumor-associated mutations in receptor tyrosine kinases (RTKs) which may also contribute to the activation of survival pathways in MM. To investigate the clinical role of RTK-mutations in MM, we deep-sequenced the coding DNA-sequence of EGFR, EPHA2, ERBB3, IGF1R, NTRK1 and NTRK2 which were previously found to be mutated in MM, in 75 uniformly treated MM patients of the “Deutsche Studiengruppe Multiples Myelom”. Subsequently, we correlated the detected mutations with common cytogenetic alterations and clinical parameters. We identified 11 novel non-synonymous SNVs or rare patient-specific SNPs, not listed in the SNP databases 1000 genomes and dbSNP, in 10 primary MM cases. The mutations predominantly affected the tyrosine-kinase and ligand-binding domains and no correlation with cytogenetic parameters was found. Interestingly, however, patients with RTK-mutations, specifically those with rare patient-specific SNPs, showed a significantly lower overall, event-free and progression-free survival. This indicates that RTK SNVs and rare patient-specific RTK SNPs are of prognostic relevance and suggests that MM patients with RTK-mutations could potentially profit from treatment with RTK-inhibitors.
KW  - multiple myeloma
KW  - rare SNP
KW  - amplicon sequencing
KW  - receptor tyrosine kinases
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-177840
VL  - 7
IS  - 25
ER  - 
TY  - THES
A1  - Leich, Ellen
T1  - Characterization of Follicular Lymphoma Lacking the Hallmark Translocation t(14;18)
T1  - Charakterisierung von t(14;18)-negativen Follikulären Lymphomen
N2  - Neoplasien des hämatopoetischen und lymphoiden Systems können in Hodkin Lymphome und in Non-Hodgkin Lymphome (NHL) unterteilt werden. Etwa 80% der NHL sind B-Zell Lymphome (B-NHL), während etwa 20% T-Zell und NK-Zell Lymphome (T-NHL) umfassen. Genetische Alterationen, insbesondere Translokationen, welche die Immunglobulin (Ig) Rezeptor Gene betreffen, sind für die Klassifikation von B-NHL von großem Nutzen und sind auch in der Pathogenese dieser Neoplasien von erheblicher Bedeutung. Ein Beispiel hierfür ist die Translokation t(14;18)(q32.33;q21.3) in follikulären Lymphomen (FL). Analog zu den Ig Rezeptor Genen in B-NHL, sind die T-Zell Rezeptor (TCR) Gene von etwa 30% der Vorläufer T-Zell Neoplasien von einer Translokation oder Inversion betroffen, die in der Regel mit der Überexpression eines Onkogens einhergehen. Die Pathogenese von reifen T-NHL, sowie deren zugrunde liegenden molekularen Mechanismen sind jedoch weitestgehend unbekannt. Um das Vorkommen und die Häufigkeit von chromosomalen Bruchpunkten im Bereich der TCR Gene in reifen T-NHL detailliert zu charakterisieren, wurden 227 Fälle im Tissue Microarray Format mit spezifischen Fluoreszenz in situ Hybridisierungs (FISH)-Assays analysiert. Translokationen oder Inversionen konnten in lediglich zwei der untersuchten Fälle nachgewiesen werden, was darauf hindeutet, dass reife T-NHL nur selten von Bruchpunkten in ihren TCR Loci betroffen sind. FL sind die zweithäufigste B-Zell Neoplasie, die durch ein vorwiegend follikuläres, follikulär und diffuses, oder durch ein vorwiegend diffuses Wachstum geprägt sein kann. Die Translokation t(14;18), die in etwa 90% der Fälle auftritt, ist mit einer deregulierten Expression des BCL2 Proto-Onkogens assoziiert. Während bereits eine Vielzahl von Studien die morphologischen, klinischen und molekularen Aspekte dieser Entität definieren konnte, fehlt eine detaillierte Charakterisierung t(14;18)-negativer FL bislang vollständig. In der vorliegenden Arbeit wurden mittels Polymerase Kettenreaktion und FISH Analyse 184 FL in t(14;18)-positive und t(14;18)-negative Fälle unterteilt, und die Genexpressionsprofile sowie die nummerischen chromosomalen Aberationen dieser Subgruppen untersucht. Die einzige genetische Alteration, die sich im Vergleich von t(14;18)-negativen und t(14;18)-positiven FL als signifikant erwies, waren Zugewinne und Amplifikationen in 18q11-q21, die in 32% der t(14;18)-positiven und in 0% der t(14;18)-negativen FL auftraten. Mit Hilfe von Genexpressionsanalysen und einer Gene Set Enrichment-Analyse (GSEA) konnte eine signifikante Assoziation von Keimzentrums B-Zell (GCB) Signaturen mit t(14;18)-positiven FL nachgewiesen werden, während in den t(14;18)-negativen FL eine signifikante Anreicherung von aktivierten B-Zell (ABC)-, NFkB-, Proliferations-, Zell Zyklus-, Interferon- und „Bystander“ Zell Signaturen beobachtet wurde. In einem immunhistochemischen Validierungsansatz mit einer unabhängigen FL Studiengruppe konnte gezeigt werden, dass der Keimzentrums Marker CD10/MME in t(14;18)-positiven FL häufiger exprimiert wird als in t(14;18)-negativen FL, während häufig eine erhöhte Expression des Post-Keimzentrums Markers IRF4/MUM1, des Proliferations Markers Ki67 und des zytotoxischen T-Zell Markers GZMB in t(14;18)-negativen FL nachweisbar war. Diese Ergebnisse weisen auf einen Post-Keimzentrums Phänotyp in t(14;18)-negativen FL hin. Das Vorkommen von „ongoing“ somatischen Hypermutationen in den schweren Ketten der Ig Gene dieser Fälle spricht jedoch gegen diese Hypothese und deutet darauf hin, dass der Phänotyp der t(14;18)-negativen FL eher dem einer B-Zelle im späten Keimzentrumsstadium entspricht. In einer unabhängigen Studie mit 35 vorwiegend diffus wachsenden FL konnte mittels immunhistochemischer Färbungen, klassischer Chromosomenbänderung, FISH und Genexpressionsanalysen eine Untergruppe von t(14;18)-negativen FL definiert werden, die sich durch eine chromosomale Deletion in 1p36 und durch spezifische morphologische und klinische Eigenschaften auszeichnete. Das Genexpressionsprofil der diffusen FL fügte sich in das Spektrum der klassischen FL ein. Mittels GSEA konnte jedoch eine signifikante Anreicherung von T-Zell-, NK-Zell- und zwei dendritischen Zell Signaturen in diesen Fällen beobachtet werden, während die Kontrollgruppe mit klassischen FL signifikant mit GCB-, Proliferations-, Zell Zyklus- und B-Zell Signaturen assoziiert war. Die diffusen FL zeichneten sich häufig durch ein frühes klinisches Stadium, sowie durch große inguinale Tumoren aus. Zusammenfassend deuten die vorliegenden Ergebnisse darauf hin, dass t(14;18)-negative FL dem Spektrum „klassischer“ FL angehören, aber dennoch spezifische molekulare und klinische Eigenschaften aufweisen. Insbesondere scheinen´t(14;18)-negative diffuse FL, die durch eine Deletion in 1p36, ein frühes klinisches Stadium und große in der Leiste lokalisierte Tumoren charakterisiert sind, eine eigene FL Subgruppe zu repräsentieren.
N2  - Tumors of the hematopoietic and lymphoid system are classified into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Approximately 80% of non-Hodgkin lymphomas (NHL) are B-cell lymphomas (B-NHL) and the remainder include T-cell and NK-cell lymphomas as well as immunodeficiency-associated lymphoproliferative disorders. The presence of genetic alterations such as translocations involving the immunoglobulin (Ig) receptor loci in B-NHL, e.g. the translocation t(14;18)(q32.33;q21.3) in follicular lymphoma (FL), are of great value for the classification and of importance in the pathogenesis of these neoplasms. In analogy to the Ig receptor genes in B-NHL, the T-cell receptor (TCR) gene loci are targeted by chromosomal breaks in approximately 30% of precursor T-cell lymphoblastic leukemias/lymphomas involving various translocation or inversion partners. Most of these events result in the overexpression of an oncogene by juxtaposing it to the regulatory sequences of the TCR genes. However, the pathogenesis of mature T-cell NHL (T-NHL) and the underlying molecular mechanisms are only poorly understood so far. To determine the exact frequency of breakpoints occurring in the TCR loci of 227 mature T-NHL cases, we designed fluorescence in situ hybridization (FISH) assays for the TCR loci that are applicable for large scale analysis of formalin fixed and paraffin embedded (FFPE) lymphoma specimens in a tissue microarray format. This approach revealed only two mature T-NHL cases with a chromosomal breakpoint in one of the TCR loci making the rearrangement of TCR loci a very rare event in these neoplasms that occurs in less than 1% of cases.FL is the second most frequent type of B-NHL that can show predominantly follicular, combined follicular and diffuse, or predominantly diffuse growth patterns. The characteristic genetic hallmark of FL is the translocation t(14;18)that occurs in approximately 90% of cases and leads to a deregulated expression of the anti-apoptotic BCL2 proto-oncogene. FL has yet been a subject of many studies deciphering morphological, clinical and molecular features of this entity. However, only little information exists about cases lacking this translocation. In this thesis we divided 184 FL cases by polymerase chain reaction (PCR) and by FISH assays into FL cases with and without t(14;18) and investigated their respective gene expression profiles and copy number alterations. For FISH analysis we followed the refined conditions established for the T-NHL study. The only genetic alterations that differed significantly by comparative genomic hybridization (CGH) analysis between FL cases with and without t(14;18) were frequent gains or amplifications in 18q11-q21 in 32% of t(14;18)-positive and 0% of t(14;18)-negative cases. Gene expression profiling and geneset enrichment analysis (GSEA) revealed an enrichment of germinal center B-cell (GCB) signatures in t(14;18)-positive cases whereas an enrichment of activated B-cell (ABC) like, NFkB-, proliferation-, cell cycle-, interferon and bystander cell signatures were observed in t(14;18)-negative cases. A validation approach by immunohistochemistry (IHC) on an independent test set of FL cases (n=84) revealed a more frequent expression of the germinal center (GC) marker CD10/MME in cases with t(14;18) and a higher expression of the post GC marker IRF4/MUM1, the proliferation marker Ki67 and the cytotoxic T-cell marker GZMB in cases without t(14;18). Although these results may suggest a post-GCB phenotype for translocation t(14;18)-negative cases, ongoing somatic hypermutations of the immunoglobulin heavy chain genes in these cases rather point to a late GC stage of B-cell differentiation in FL without t(14;18). In an independent study with 35 predominantly diffuse FL cases, it was furthermore possible to define another subset of t(14;18)-negative FL characterized by a chromosomal deletion (del) in 1p36 and distinct morphological and clinical features by IHC, classical chromosome banding, FISH and gene expression profiling. The gene expression profiles of predominantly diffuse FL cases fell into the spectrum of FL. However, by GSEA they showed a significant enrichment of T-cell, NK-cell- and two dendritic-cell subset signatures, whereas a significant enrichment of GCB cell-, proliferation-, cell cycle- and B-cell signatures was observed in a control group of “classic” FL cases. Remarkably, patients with diffuse FL frequently presented with low clinical stage and large, but localized inguinal tumors. In conclusion, our results suggest that t(14;18)-negative FL are part of the spectrum of FL in general, but nevertheless show distinct molecular and clinical features. In particular, predominantly diffuse FL with (del)1p36, low clinical stage and large but localized inguinal tumors may represent a distinct t(14;18)-negative FL subtype.
KW  - Keimzentrum
KW  - Non Hodgkin Lymphome
KW  - BCL2
KW  - Immunrezeptoren
KW  - Non Hodgkin Lymphoma
KW  - BCL2
KW  - Immunoreceptors
Y1  - 2009
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-38998
ER  - 
TY  - JOUR
A1  - Leich, Ellen
A1  - Maier, Claudia
A1  - Bomben, Riccardo
A1  - Vit, Filippo
A1  - Bosi, Alessandro
A1  - Horn, Heike
A1  - Gattei, Valter
A1  - Ott, German
A1  - Rosenwald, Andreas
A1  - Zamò, Alberto
T1  - Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage
JF  - Blood Advances
N2  - We previously reported that t(14;18)-negative follicular lymphomas (FL) show a clear reduction of newly acquired N-glycosylation sites (NANGS) in immunoglobulin genes. We therefore aimed to investigate in-depth the occurrence of NANGS in a larger cohort of t(14;18)-positive and t(14;18)-negative FL, including early (I/II) and advanced (III/IV) stage treatment-naive and relapsed tumors. The clonotype was determined by using a next-generation sequencing approach in a series of 68 FL with fresh frozen material [36 t(14;18) positive and 32 t(14;18) negative]. The frequency of NANGS differed considerably between t(14;18)-positive and t(14;18)-negative FL stage III/IV, but no difference was observed among t(14;18)-positive and t(14;18)-negative FL stage I/II. The introduction of NANGS in all t(14;18)-negative clinical subgroups occurred significantly more often in the FR3 region. Moreover, t(14;18)-negative treatment-naive FL, specifically those with NANGS, showed a strong bias for IGHV4-34 usage compared with t(14;18)-positive treatment-naive cases with NANGS; IGHV4-34 usage was never recorded in relapsed FL. In conclusion, subgroups of t(14;18)-negative FL might use different mechanisms of B-cell receptor stimulation compared with the lectin-mediated binding described in t(14;18)-positive FL, including responsiveness to autoantigens as indicated by biased IGHV4-34 usage and strong NANGS enrichment in FR3.
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-363378
VL  - 5
ER  - 
TY  - JOUR
A1  - Leich, Ellen
A1  - Schreder, Martin
A1  - Pischimarov, Jordan
A1  - Stühmer, Thorsten
A1  - Steinbrunn, Torsten
A1  - Rudelius, Martina
A1  - Brünnert, Daniela
A1  - Chatterjee, Manik
A1  - Langer, Christian
A1  - Keppler, Sarah
A1  - Heredia-Guerrero, Sofia Catalina
A1  - Einsele, Hermann
A1  - Knop, Stefan
A1  - Bargou, Ralf Christian
A1  - Rosenwald, Andreas
T1  - Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
JF  - Blood Cancer Journal
N2  - No abstract available.
KW  - cancer genetics
KW  - cancer genomics
KW  - cancer therapy
KW  - myeloma
KW  - translational research
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-363410
VL  - 11
ER  - 
TY  - JOUR
A1  - Ronchi, Cristina L.
A1  - Leich, Ellen
A1  - Sbiera, Silviu
A1  - Weismann, Dirk
A1  - Rosenwald, Andreas
A1  - Allolio, Bruno
A1  - Fassnacht, Martin
T1  - Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways
JF  - Neoplasia
N2  - The genetic mechanisms underlying adrenocortical tumor development are still largely unknown. We used high-resolution single nucleotide polymorphism microarrays (Affymetrix SNP 6.0) to detect copy number alterations (CNAs) and copy-neutral losses of heterozygosity (cnLOH) in 15 cortisol-secreting adrenocortical adenomas with matched blood samples. We focused on microalterations aiming to discover new candidate genes involved in early tumorigenesis and/or autonomous cortisol secretion. We identified 962 CNAs with a median of 18 CNAs per sample. Half of them involved noncoding regions, 89% were less than 100 kb, and 28% were found in at least two samples. The most frequently gained regions were 5p15.33, 6q16.1, 7p22.3-22.2, 8q24.3, 9q34.2-34.3, 11p15.5, 11q11, 12q12, 16q24.3, 20p11.1-20q21.11, and Xq28 (>= 20% of cases), most of them being identified in the same three adenomas. These regions contained among others genes like NOTCH1, CYP11B2, HRAS, and IGF2. Recurrent losses were less common and smaller than gains, being mostly localized at 1p, 6q, and 11q. Pathway analysis revealed that Notch signaling was the most frequently altered. We identified 46 recurrent CNAs that each affected a single gene (31 gains and 15 losses), including genes involved in steroidogenesis (CYP11B1) or tumorigenesis (CTNNB1, EPHA7, SGK1, STIL, FHIT). Finally, 20 small cnLOH in four cases affecting 15 known genes were found. Our findings provide the first high-resolution genome-wide view of chromosomal changes in cortisol-secreting adenomas and identify novel candidate genes, such as HRAS, EPHA7, and SGK1. Furthermore, they implicate that the Notch1 signaling pathway might be involved in the molecular pathogenesis of adrenocortical tumors.
KW  - kinase
KW  - comparative genomic hybridization
KW  - high-resolution analysis
KW  - Cushings syndrome
KW  - neutral loss
KW  - tumors
KW  - serum
KW  - expression
KW  - carcinoma
KW  - catenin
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134953
VL  - 14
IS  - 3
ER  - 
TY  - JOUR
A1  - Rudelius, Martina
A1  - Rosenfeldt, Mathias Tillmann
A1  - Leich, Ellen
A1  - Rauert-Wunderlich, Hilka
A1  - Solimando, Antonio Giovanni
A1  - Ott, German
A1  - Rosenwald, Andreas
A1  - Beilhack, Andreas
T1  - Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
JF  - Haematologica
N2  - Mantle cell lymphoma and other lymphoma subtypes often spread to the bone marrow, and stromal interactions mediated by focal adhesion kinase frequently enhance survival and drug resistance of the lymphoma cells. To study the role of focal adhesion kinase in mantle cell lymphoma, immunohistochemistry of primary cases and functional analysis of mantle cell lymphoma cell lines and primary mantle cell lymphoma cells co-cultured with bone marrow stromal cells (BMSC) using small molecule inhibitors and RNAi-based focal adhesion kinase silencing was performed. We showed that focal adhesion kinase is highly expressed in bone marrow infiltrates of mantle cell lymphoma and in mantle cell lymphoma cell lines. Stroma-mediated activation of focal adhesion kinase led to activation of multiple kinases (AKT, p42/44 and NF-kappa B), that are important for prosurvival and proliferation signaling. Interestingly, RNAi-based focal adhesion kinase silencing or inhibition with small molecule inhibitors (FAKi) resulted in blockage of targeted cell invasion and induced apoptosis by inactivation of multiple signaling cascades, including the classic and alternative NF-kappa B pathway. In addition, the combined treatment of ibrutinib and FAKi was highly synergistic, and ibrutinib resistance of mantle cell lymphoma could be overcome. These data demonstrate that focal adhesion kinase is important for stroma-mediated survival and drug resistance in mantle cell lymphoma, providing indications for a targeted therapeutic strategy.
KW  - NF-Kappa-B
KW  - Stromal cells
KW  - Induced apoptosis
KW  - Fak regulation
KW  - Phase-
KW  - Multiple
KW  - Activation
KW  - Mechanisms
KW  - Migration
KW  - Pathogenesis
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227117
VL  - 103
IS  - 1
ER  - 
TY  - JOUR
A1  - Sbiera, Silviu
A1  - Ronchi, Cristina L.
A1  - Leich, Ellen
A1  - Henzel, Katharina
A1  - Rosenwald, Andreas
A1  - Allolio, Bruno
A1  - Fassnacht, Martin
T1  - Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?
JF  - PLoS ONE
N2  - Adrenocortical tumors consist of benign adenomas and highly malignant carcinomas with a still incompletely understood pathogenesis. A total of 46 adrenocortical tumors (24 adenomas and 22 carcinomas) were investigated aiming to identify novel genes involved in adrenocortical tumorigenesis. High-resolution single nucleotide polymorphism arrays (Affymetrix) were used to detect copy number alterations (CNAs) and copy neutral losses of heterozygosity (cnLOH). Genomic clustering showed good separation between adenomas and carcinomas, with best partition including only chromosome 5, which was highly amplified in 17/22 malignant tumors. The malignant tumors had more relevant genomic aberrations than benign tumors, such as a higher median number of recurrent CNA (2631 vs 94), CNAs >100 Kb (62.5 vs 7) and CN losses (72.5 vs 5.5), and a higher percentage of samples with cnLOH (91% vs 29%). Within the carcinoma cohort, a precise genetic pattern (i.e. large gains at chr 5, 7, 12, and 19, and losses at chr 1, 2, 13, 17, and 22) was associated with a better prognosis (overall survival: 72.2 vs 35.4 months, P=0.063). Interestingly, >70% of gains frequent in beningn were also present in malignant tumors. Notch signaling was the most frequently involved pathway in both tumor entities. Finally, a CN gain at imprinted “IGF2” locus chr 11p15.5 appeared to be an early alteration in a multi-step tumor progression, followed by the loss of one or two alleles, associated with increased IGF2 expression, only in carcinomas. Our study serves as database for the identification of genes and pathways, such as Notch signaling, which could be involved in the pathogenesis of adrenocortical tumors. Using these data, we postulate an adenoma-carcinoma sequence for these tumors.
KW  - adenomas
KW  - cancer diagnosis
KW  - cancer detection
KW  - carcinogenesis
KW  - carcinomas
KW  - chromosomes
KW  - genetic loci
KW  - malignant tumors
KW  - notch signaling
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97218
ER  -